Immunotherapies targeting the PDL1-PD1 axis have entered standard clinical practice for various solid cancers including (non-small cell lung cancer, gastric cancer, urothelial cancer, cervical cancer, and melanoma) [51,52,53,54]. Here, CD274 is linked to non-small cell lung carcinoma.